[1]迟凯耀,贾凯,张祝强,等.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）眼表感染研究进展[J].眼科新进展,2021,41(9):892-896.[doi:10.13389/j.cnki.rao.2021.0187]
　CHI Kaiyao,JIA Kai,ZHANG Zhuqiang,et al.Research progress of severe acute respiratory syndrome coronavirus 2 in ocular surface infection[J].Recent Advances in Ophthalmology,2021,41(9):892-896.[doi:10.13389/j.cnki.rao.2021.0187]
点击复制

严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）眼表感染研究进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年9期
页码:
892-896
栏目:
文献综述
出版日期:
2021-09-05

文章信息/Info

Title:
Research progress of severe acute respiratory syndrome coronavirus 2 in ocular surface infection
作者:
迟凯耀; 贾凯; 张祝强; 潘禹硕; 赵磊; 左韬
110032　辽宁省沈阳市，辽宁中医药大学(迟凯耀，潘禹硕)；230000　安徽省合肥市，安徽中医药大学（贾凯）；110034　辽宁省沈阳市，辽宁中医药大学附属第二医院眼科(张祝强，赵磊，左韬)
Author(s):
CHI Kaiyao1; JIA Kai2; ZHANG Zhuqiang3; PAN Yushuo1; ZHAO Lei3; ZUO Tao3
1.Liaoning University of Traditional Chinese Medicine,Shenyang 110032,Liaoning Province,China
2.Anhui University of Chinese Medicine,Hefei 230000,Anhui Province,China
3.The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110034,Liaoning Province,China
关键词:
严重急性呼吸综合征冠状病毒2型; COVID-19; 眼表; 感染途径
Keywords:
SARS-CoV-2;  COVID-19;  ocular surface;  route of infection
分类号:
R373.9; R511; R777.31
DOI:
10.13389/j.cnki.rao.2021.0187
文献标志码:
A
摘要:
严重急性呼吸综合征冠状病毒2型（SARS-CoV-2，又称COVID-19）经眼表传播远较经口鼻传播困难，然而现有证据认为眼表传播仍是一条可能的途径，尤其对于医护人员。本文描述了SARS-CoV-2相关的眼表症状，阐释了眼表SARS-CoV-2入胞的可能机制和与眼表相关的SARS-CoV-2传播机制，并对现有的和未来可能的研究方向进行了剖析，为从眼表考虑临床治疗SARS-CoV-2提供新的思路与方法，帮助人们研发出更多的治疗策略。
Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, is much more difficult to transmit through the ocular surface than that through the mouth and nose. However, the available evidence has suggested the possibility of ocular surface transmission, especially in medical staff. In this paper, we describe the existing SARS-CoV-2 ocular surface symptoms, the possible mechanism of SARS-COV-2 entering ocular surface cells and SARS-COV-2 transmission through ocular surface. In addition, the existing and future possible research directions of SARS-CoV-2 transmission through ocular surface were analyzed, so as to provide new ideas and methods for clinical treatment of SARS-CoV-2 from the perspective of ocular surface.

参考文献/References:

［1］　VAN DER HOEK L.Human coronaviruses:what do they cause?［J］.Antivir Ther,2007,12(4):651-658.
［2］　LU R,ZHAO X,LI J,NIU P,YANG B,WU H,et al.Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding［J］.Lancet,2020,395(1224):565-574.
［3］　ZHU N,ZHANG D Y,WANG W L,LI X W,YANG B,SONG J D,et al.A novel coronavirus from patients with pneumonia in China,2019［J］.N Engl J Med,2020,382(8):727-733.
［4］　JASPER F C,KIN-HANG K,ZHENG Z,HIN C,KELVIN K T,YUAN S F,et al.Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan［J］.Emerg Microbes Infect,2020,9(1):221-236.
［5］　FEHR A R,PERLMAN S.Coronaviruses:an overview of their replication and pathogenesis［J］.Methods Mol Biol,2015,1282:1-23.
［6］　XIA S,LIU M,WANG C,XU W,LAN Q,FENG S L,et al.Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion［J］.Cell Res,2020,30(4):343-355.
［7］　ASHOUR H M,ELKHATIB W F,RAHMAN M M,ELSHABRAWY H A.Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks［J］.Pathogens,2020,9(3):186.
［8］　SUNGNAK W,HUANG N,BCAVIN C,BERG M,QUEEN R,LITVINUKOVA M,et al.SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes［J］.Nat Med,2020,26(5):681-687.
［9］　YAN R,ZHANG Y,LI Y,XIA L,GUO Y Y,ZHOU Q.Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2［J］.Science,2020,367(6485):1444-1448.
［10］　MARKUS H,KLEINE-WEBER H,SCHROEDER S,KRGER N,TANJA H,ERICHSEN S,et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor［J］.Cell,2020,181(2):271-280.
［11］　ULRICH H,PILLAT M M.CD147 as a target for COVID-19 treatment:suggested effects of azithromycin and stem cell engagement［J］.Stem Cell Rev Rep,2020,16(3):434-440.
［12］　OU X,LIU Y,LEI X,LI P,MI D,REN L,et al.Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV［J］.Nat Commun,2020,11(1):1620.
［13］　SIMMONS G,GOSALIA D N,RENNEKAMP A J,REEVES J D,DIAMOND S L,BATES P.Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry［J］.Proc Natl Acad Sci U S A,2005,102(33):11876-11881.
［14］　ZHOU L L,XU Z H,CASTIGLIONE G M,SOIBERMAN U S,EBERHART C G,DUH E J.ACE2 and TMPRSS2 are expressed on the human ocular surface,suggesting susceptibility to SARS-CoV-2 infection［J］.Ocul Surf,2020,18(4):537-544.
［15］　张碧凝,王群,刘廷,窦圣乾,祁霞,姜慧,等.新型冠状病毒相关蛋白ACE2和TMPRSS2在眼部组织的表达分析［J］.中华眼科杂志,2020,56(6):438-446.
ZHANG B N,WANG Q,LIU T,DOU S Q,QI X,JIANG H,et al.Expression analysis of 2019-nCoV related ACE2 and TMPRSS2 in eye tissues［J］.Chin J Ophthalmol,2020,56(6):438-446.
［16］　HEURICH A,HOFMANN-WINKLER H,GIERER S,LIEPOLD T,JAHN O,PHLMANN S.TMPRSS2 and Adam17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein［J］.J Virol,2014,88(2):1293-1307.
［17］　DAI H,ZHANG X,XIA J,ZHANG T,SHANG Y,HUANG R,et al.High-resolution chest CT features and clinical characteristics of patients infected with COVID-19 in Jiangsu,China［J］.Int J Infect Dis,2020,95:106-112.
［18］　BARNETT B P,WAHLIN K,KRAWCZYK M,SPENCER D,WELSBIE D,AFSHARI N,et al.Potential of ocular transmission of SARS-CoV-2:a review［J］.Vision (Basel),2020,4(3):40.
［19］　CHEN N,ZHOU M,DONG X,QU J,GONG F,HAN Y,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study［J］.Lancet,2020,395(1223):507-513.
［20］　ZHANG J J,DONG X,CAO Y Y,YUAN Y D,YANG Y B,YAN Y Q,et al.Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan,China［J］.Allergy,2020,75(7):1730-1741.
［21］　ZHU W,XIE K,LU H,XU L,ZHOU S,FANG S.Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei,China［J］.J Med Virol,2020,92(9):1525-1532.
［22］　叶娅,宋艳萍,闫明,胡城,陈晓,喻娟,等.新型冠状病毒肺炎合并结膜炎三例［J］.中华实验眼科杂志,2020,38(3):242-244.
YE Y,SONG Y P,YAN M,HU C,CHEN X,YU J,et al.Novel coronavirus pneumonia combined with conjunctivitis:three cases report［J］.Chin J Exp Ophthalmol,2020,38(3):242-244.
［23］　ZHANG X,CHEN X,CHEN L,DENG C,ZOU X,LIU W,et al.The evidence of SARS-CoV-2 infection on ocular surface［J］.Ocul Surf,2020,18(3):360-362.
［24］　WU P,DUAN F,LUO C,LIU Q,QU X,LIANG L,et al.Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei province,China［J］.JAMA Ophthalmol,2020,138(5):575-578.
［25］　LU C W,LIU X F,JIA Z F.2019-nCoV transmission through the ocular surface must not be ignored［J］.Lancet,2020,395(10223):497-506.
［26］　PING W,LIANG L,CHEN C B,NIE S Q.A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis［J］.Graefes Arch Clin Exp Ophthalmol,2020,258(7):1565-1566.
［27］　WHO-China Joint Mission.Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19)［R］.Geneva:World Health Organization,2020.
［28］　CHEEMA M,AGHAZADEH H,NAZARALI S,TING A,HODGES J,MCFARLANE A,et al.Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19)［J］.Can J Ophthalmol,2020,55(4):e125-e129.
［29］　COLAVITA F,LAPA D,CARLETTI F,LALLE E,BORDI L,MARSELLA P,et al.SARS-CoV-2 isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection［J］.Ann Intern Med,2020,173(3):242-243.
［30］　KHAVANDI S,TABIBZADEH E,NADERAN M,SHOAR S.Corona virus disease-19 (COVID-19) presenting as conjunctivitis:atypically high-risk during a pandemic［J］.Cont Lens Anterior Eye,2020,43(3):211-212.
［31］　SEAH I,ANDERSON D E,KANG A,WANG L,RAO P,YOUNG B E,et al.Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients［J］.Ophthalmology,2020,127(7):977-979.
［32］　SUN C B,WANG Y Y,LIU G H,LIU Z.Role of the eye in transmitting human coronavirus:what we know and what we do not know?［J］.Front Public Health,2020,8:155.
［33］　SCALINCI S Z,TROVATO B E.Conjunctivitis can be the only presenting sign and symptom of COVID-19［J］.IDCases,2020,20:e00774.
［34］　XIA J,TONG J P,LIU M Y,SHEN Y,GUO D.Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection［J］.J Med Virol,2020,92(6):589-594.
［35］　CHU D K,AKL E A,DUDA S,SOLO K,YAACOUB S,SCHNEMANN H J,et al.Physical distancing,face masks,and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19:a systematic review and meta-analysis［J］.Lancet,2020,395(1242):1973-1987.
［36］　LIU Z,SUN C B.Conjunctiva is not a preferred gateway of entry for SARS-CoV-2 to infect respiratory tract［J］.J Med Virol,2020,92(9):1410-1412.
［37］　BHASKAR M E,ARUN S.SARS-CoV-2 infection among community health workers in India before and after use of face shields［J］.JAMA,2020,324(13):1348-1349.
［38］　LI J O,LAM D,CHEN Y,TING D.Novel coronavirus disease 2019 (COVID-19):the importance of recognising possible early ocular manifestation and using protective eyewear［J］.Br J Ophthalmol,2020,104(3):297-298.
［39］　国家卫生健康委办公厅,国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案（试行第七版）［EB/OL］.［2020-03-03］.http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
National Health Commission of the People’s Republic of China,National Administration of Traditional Chinese Medicine.Diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 7) ［EB/OL］.［2020-03-03］.http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
［40］　KAWASE M,SHIRATO K,VAN DER HOEK L,TAGUCHI F,MATSUYAMA S.Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry［J］.J Virol,2012,86(12):6537-6545.
［41］　MONTEIL V,KWON H,PRADO P,HAGELKRYS A,WIMMER R A,STAHL M,et al.Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2［J］.Cell,2020,181(4):905-913.
［42］　SONG C Y,XU J,HE J Q,LU Y Q.Immune dysfunction following COVID-19,especially in severe patients［J］.Sci Rep,2020,10(1):15838.
［43］　BONAM S R,KAVERI S V,SAKUNTABHAI A,GILARDIN L,BAYRY J.Adjunct immunotherapies for the management of severely ill COVID-19 patients［J］.Cell Rep Med,2020,1(2):100016.
［44］　DYE B R,HILL D R,FERGUSON M,TSAI Y H,NAGY M S,DYAL R,et al.In vitro generation of human pluripotent stem cell derived lung organoids［J］.Elife,2015,4:e05098.
［45］　FOSTER J W,WAHLIN K,ADAMS S M,BIRK D,ZACK D J,CHAKRAVARTI S.Cornea organoids from human induced pluripotent stem cells［J］.Sci Rep,2017,7:41286.
［46］　LEUNG L S,NEAL J W,HA W E,SEQUIST L,MARMOR M F.Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy［J］.Am J Ophthalmol,2015,160(4):799-805.

相似文献/References:

[1]雷涛,王润生,张博,等.COVID-19感染相关视网膜中央动脉阻塞患者的眼底影像特征[J].眼科新进展,2023,43(11):893.[doi:10.13389/j.cnki.rao.2023.0179]
　LEI Tao,WANG Runsheng,ZHANG Bo,et al.Fundus imaging features of patients with COVID-19 infection-associated central retinal artery occlusion[J].Recent Advances in Ophthalmology,2023,43(9):893.[doi:10.13389/j.cnki.rao.2023.0179]

备注/Memo

备注/Memo:
财政部中医药循证能力建设项目(编号：2019XZZX-YK008)；辽宁省自然科学基金项目(编号：20170540557)
更新日期/Last Update: 2021-09-05